Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE) -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (124)	1/9/2007 10:52:50 AM
From: tuck	Read Replies (2) \| Respond to of 250

>>Supreme Court reverses MedImmune dismissal High court disagrees with federal appeals court that threw out a suit challenging Genentech's patent on producing cancer drugs. January 9 2007: 10:31 AM EST WASHINGTON (Reuters) -- The U.S. Supreme Court on Tuesday reversed a federal court decision that threw out a MedImmune Inc. lawsuit challenging the validity of a key Genentech Inc. patent. In a decision closely watched by U.S. patent experts, the high court disagreed with a federal appeals court that dismissed a suit aimed at overturning a patent covering a method of producing antibody drugs, including Genentech's cancer treatments Avastin and Rituxan.<< Cabilly patent back in play, I guess. I presume the case is being remanded. Cheers, Tuck